US Patent 12,364,700 for Linagliptin Plus Metformin in Type 2 Diabetes With CKD Albuminuria and Macrovascular Disease: Scope, Claim Boundaries, and Patent Landscape
US Patent 12,364,700 is a US method-of-treatment claim set that centers on using linagliptin plus metformin in patients with type 2 diabetes who have chronic kidney disease (eGFR down to 30 mL/min/1.73 m²) plus albuminuria and a history of macrovascular disease (eg, prior MI, stroke, PAD, carotid disease, high-risk CAD). The claims tighten scope through (i) renal function thresholds, (ii) albuminuria definition, (iii) macrovascular history definition, and (iv) specific fixed-dose combinations and dosing schedules, including single-composition administration of linagliptin and immediate-release or extended-release metformin strengths.
What does US 12,364,700 claim for linagliptin plus metformin in type 2 diabetes with CKD and albuminuria?
Core claimed concept (Claim 1). A treatment method for a type 2 diabetes patient with:
- eGFR as low as 30 mL/min/1.73 m²
- albuminuria
- previous macrovascular disease
- administered linagliptin (or a pharmaceutically acceptable salt) in combination with metformin
- optional further agents: insulin and/or a sulfonylurea
Regimen architecture. The claim is not limited to a particular dosing frequency by default. It sets the “who” (renal + albuminuria + macrovascular history) and “what” (linagliptin + metformin; optional insulin/sulfonylurea) and leaves “how” open until dependent claims narrow dosing form and strength.
How do the dependent claims narrow patient eligibility?
Claims 2, 11-14, and 15 progressively constrain renal function and clinical descriptors.
- Claim 2: eGFR down to 45 mL/min/1.73 m²
- Claim 11: eGFR 30-60
- Claim 12: eGFR 45-59
- Claim 13: eGFR 30-44
- Claim 14: renal impairment with eGFR ≥45-75 and macro-albuminuria
- Claim 15: defines albuminuria and macrovascular disease with specific criteria and enumerated categories; also defines alternative “impaired renal function” criteria using both eGFR bands and UACR thresholds.
Albuminuria definition in Claim 15
Albuminuria is defined by any of:
- UACR ≥ 30 mg/g creatinine
- or ≥ 30 mg/L
- or ≥ 30 μg/min
- or ≥ 30 mg/24h
Macrovascular disease definition in Claim 15
“Previous macrovascular disease” includes one or more of:
- previous MI
- advanced coronary artery disease
- high-risk single-vessel coronary artery disease
- previous ischemic or hemorrhagic stroke
- carotid artery disease
- peripheral artery disease
Impaired renal function definitions in Claim 15
Two alternative constructs are set out:
- eGFR 15 or 30-45 mL/min/1.73 m² with any UACR
- eGFR ≥45-75 mL/min/1.73 m² with UACR >200 (plus equivalent unit thresholds)
How do the dependent claims narrow the dosing form and strength?
A key boundary of US 12,364,700 is that it moves from “combination treatment” to specific fixed-dose composition configurations and specific release forms.
Single composition administration (Claims 3, 10)
- Claim 3: linagliptin + metformin in a single pharmaceutical composition
- Claim 10: single oral dosage form comprising:
- 2.5 mg linagliptin + 500 mg metformin
- administered twice daily
- patient must have eGFR 30-44, and must have albuminuria + previous macrovascular disease
This claim is likely the most “design-around-sensitive” because it specifies both the dose combination and BID schedule.
Linagliptin dosage strength options (Claims 4, 8-9)
- Claim 4: composition includes linagliptin 2.5 mg or 5 mg
- Claim 8: total oral daily linagliptin dose 5 mg
- Claim 9: 5 mg total daily dose can be 2.5 mg twice daily or 5 mg once daily
Metformin release type and strength matrices (Claim 5, 7)
- Claim 5: metformin strengths differ by release:
- Immediate release (IR): 500 mg, 850 mg, 1000 mg
- Extended release (ER): 500 mg, 750 mg, 1000 mg, 1500 mg, 2000 mg
- Claim 6: example fixed-dose composition:
- 2.5 mg linagliptin + 500 mg metformin (IR)
- Claim 7: example fixed-dose compositions:
- 5 mg linagliptin + 1000 mg metformin (ER)
- OR 2.5 mg linagliptin + 750 mg (ER)
- OR 2.5 mg linagliptin + 1000 mg (ER)
What additional co-therapies are expressly covered? (Claims 16-18)
The patent is framed to cover “stacked” cardiometabolic regimens.
- Claim 16: add at least one blood-pressure lowering active substance
- Claim 17: add at least one lipid-lowering active substance
- Claim 18: add aspirin
These dependent claims broaden infringement risk beyond just antidiabetic therapy by tying the method to common secondary prevention measures. They also create potential overlap with standard-of-care CAD/vascular risk management.
When does linagliptin plus metformin in CKD with albuminuria lose exclusivity under US Patent 12,364,700?
Timing depends on two separate clocks:
- Patent term under US law (generally 20 years from earliest effective non-provisional filing date, subject to adjustments and extensions).
- Any FDA-related exclusivities (12-year exclusivity, 3-year exclusivity, and patent-term adjustment/extension), which apply to an NDA/BLA product depending on regulatory history.
The claim set you provided does not include:
- the patent’s filing date
- earliest priority date
- PTE/PTE claim information
- the FDA reference product tied to this method (linagliptin + metformin combination may map to multiple brands and submissions)
Without those data, a complete, accurate exclusivity timeline cannot be produced.
What patent estate surrounds US 12,364,700: continuation families, formulation IP, and method-of-use coverage?
Using only the claim text, the patent clearly sits in a method-of-use space with strong boundaries at:
- patient phenotype (T2D + CKD by eGFR plus albuminuria plus prior macrovascular disease)
- drug pairing (linagliptin + metformin)
- combination presentation and strength (2.5/5 mg linagliptin; metformin IR vs ER strength bands; single tablet requirement in certain claims)
- dose schedule (notably BID for the 2.5 mg/500 mg twice daily example)
In practical landscape terms, such patents typically coexist with three other IP tiers:
- Composition-of-matter patents for linagliptin (and salts) and metformin formulations (often long-expired or outside the combination-specific novelty window).
- Combination product formulation patents (tablet design, ER/IR metformin release properties, fixed-dose ratio tablets, patient compliance dosing).
- Additional method-of-use patents for related comorbid phenotype subsets (eg, specific eGFR strata, albuminuria cutpoints, specific cardiovascular endpoints, or combinations with SGLT2 inhibitors/GLP-1 receptor agonists).
But the claim text alone does not identify:
- related US application numbers
- continuation counts
- assignees
- CPC classes
- family members in EPO/WO
- whether this patent is the primary or a later publication in the family
So a complete “how many patents cover this exact clinical population” assessment is not possible from the prompt alone.
What is the likely claim scope risk: generic entry or biosimilar pathways?
Biosimilar risk
This is a small-molecule method-of-use patent covering linagliptin and metformin. Biosimilar pathways do not apply.
Generic entry risk
Risk comes from:
- the FDA approval pathway for linagliptin + metformin fixed-dose combination products (if any) and
- the likelihood that label instructions or real-world prescribing match the claim’s phenotype plus co-therapy requirements.
Because the independent claim (Claim 1) covers combination administration to a defined patient phenotype, infringement risk can attach to prescribing and dosing if clinical practice uses the claimed regimen and patient criteria.
Dependent claims 3-7 and 9-10 are more sensitive:
- they require single composition and specific dose strengths and metformin IR/ER selection
- they require specific BID schedule for the 2.5 mg/500 mg fixed-dose twice daily example
A generic manufacturer can reduce exposure by avoiding those exact dose-schedule combinations, but the broader Claim 1 still targets the treatment concept even if a different strength pair is used (unless the claims are construed narrowly by the court to require fixed-dose administration elements).
Which specific medical subgroups does US 12,364,700 target for infringement exposure?
US 12,364,700 targets a tight clinical intersection that is likely to map to cardiometabolic secondary prevention cohorts.
High-risk phenotype buckets (from Claim 15):
- T2D with prior MI or stroke or carotid/PAD
- with albuminuria ≥30 mg/g (or equivalent units)
- with CKD:
- eGFR 30-45 (or 15-30) with any UACR
- or eGFR ≥45-75 with UACR >200
Secondary bucket (Claims 2, 10, 12, 13):
- eGFR banding down to 30-44 or 45-59
- with albuminuria and prior macrovascular disease
How does the patent handle administration details: single tablet and release form?
This is a core scoping lever.
- Claim 3 requires single pharmaceutical composition for one set of limitations.
- Claims 5-7 define metformin release type:
- IR: 500, 850, 1000 mg
- ER: 500, 750, 1000, 1500, 2000 mg
- Claim 10 defines a very specific fixed-dose BID schedule:
- 2.5 mg linagliptin + 500 mg metformin
- twice daily
- eGFR 30-44
- plus albuminuria + prior macrovascular disease
From an infringement mechanics standpoint, the single composition and release-type constraints make it easier to map alleged infringement to specific product label strengths and prescribing patterns.
What co-therapy elements are included beyond linagliptin and metformin?
The patent explicitly adds standard cardiometabolic and vascular risk therapies.
- Blood pressure lowering active (Claim 16)
- Lipid lowering active (Claim 17)
- Aspirin (Claim 18)
These broaden real-world match probability because many patients with the claimed macrovascular disease history are concurrently on antiplatelet and lipid/BP therapies.
What litigation or Orange Book status affects US 12,364,700 enforcement?
The prompt provides:
- the patent number and claim text only
- no Orange Book listings
- no FDA NDA/BLA numbers
- no Paragraph IV challenges
- no litigation dockets or settlement dates
A complete, accurate status report (Orange Book listing, listed patents, expiring patents, or any Hatch-Waxman litigation tied to this specific patent) cannot be constructed without those facts.
How strong is the patent estate for protecting linagliptin + metformin in CKD albuminuria with prior macrovascular disease?
Based strictly on claim breadth, US 12,364,700 has two layers of enforceability:
Layer 1 (broader independent claim):
- treats a defined patient phenotype (eGFR down to 30; albuminuria; prior macrovascular disease)
- uses a defined drug pairing (linagliptin + metformin)
- allows optional insulin and/or sulfonylurea
Layer 2 (narrower dependent claims):
- single composition requirement
- fixed dose linagliptin strengths
- IR vs ER metformin strength matrices
- specific dosing schedules and a specific 2.5/500 BID example
This structure usually supports both:
- broad coverage through the independent claim (concept-level infringement risk)
- product-specific coverage through the dependent claims (stronger mapping to specific fixed-dose products)
Does US 12,364,700 overlap with other DPP-4 inhibitor or metformin combination IP?
The claim is specific to linagliptin + metformin and specific patient phenotype constraints. Overlap with other DPP-4 inhibitors (eg, sitagliptin, saxagliptin) is not explicit in the claim text because the method requires linagliptin.
However, in practice, landscape overlap can occur via:
- shared cardiometabolic secondary prevention themes (albuminuria + prior macrovascular disease)
- shared CKD staging by eGFR and UACR thresholds
- shared fixed-dose metformin ER/IR strength matrices
Without the publication set and the family map, it is not possible to quantify overlap among related method-of-use patents in the same indication.
Key Takeaways
- US 12,364,700 is a method-of-treatment patent for type 2 diabetes with CKD (eGFR down to 30) plus albuminuria and previous macrovascular disease, using linagliptin + metformin.
- Claim scope tightens through renal strata (eGFR bands), albuminuria cutpoints (UACR thresholds), and macrovascular history enumeration.
- The patent includes composition and dosing specificity: single composition administration, linagliptin strength options (2.5 mg, 5 mg; 5 mg total daily), metformin IR vs ER strength matrices, and a specific fixed-dose example (2.5 mg/500 mg BID for eGFR 30-44).
- The dependent claims add realistic real-world co-therapy elements (BP lowering agents, lipid lowering agents, aspirin), which increases practical match likelihood.
- A complete exclusivity timeline, Orange Book status, and litigation/Paragraph IV risk profile cannot be generated from the provided information alone.
FAQs
-
Does US 12,364,700 require a specific metformin release form to infringe Claim 1?
Claim 1 covers “linagliptin in combination with metformin” without requiring IR vs ER; IR/ER constraints appear in dependent composition/dose claims.
-
What are the key eGFR and UACR thresholds that define the protected patient population?
eGFR down to 30 in Claim 1; albuminuria examples include UACR ≥30 mg/g; additional impaired renal function constructs include eGFR ≥45-75 with UACR >200.
-
Is aspirin included only as optional co-therapy or as a claim limitation?
Aspirin is expressly included in a dependent claim (Claim 18), creating a separate limited method scope.
-
Can prescribing a different fixed-dose linagliptin/metformin strength avoid the dependent claims?
Dependent claims 6-7 and 10 target specific combinations and schedules; however, Claim 1 can still be implicated if the regimen falls within the independent claim’s broader treatment concept.
-
Is biosimilar competition relevant to this patent?
No. The claims are directed to small molecules (linagliptin and metformin), not biologics.
References (APA)
- United States Patent 12,364,700. (Claims as provided in the prompt).
